Edwards Lifesciences
1,259 hedge funds and large institutions have $39.4B invested in Edwards Lifesciences in 2025 Q2 according to their latest regulatory filings, with 164 funds opening new positions, 423 increasing their positions, 458 reducing their positions, and 93 closing their positions.
76% more first-time investments, than exits
New positions opened: 164 | Existing positions closed: 93
70% more call options, than puts
Call options by funds: $254M | Put options by funds: $149M
8% more capital invested
Capital invested by funds: $36.6B → $39.4B (+$2.79B)
5% more funds holding
Funds holding: 1,204 → 1,259 (+55)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
0.57% less ownership
Funds ownership: 86.28% → 85.71% (-0.57%)
8% less repeat investments, than reductions
Existing positions increased: 423 | Existing positions reduced: 458
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$359M |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$358M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$288M |
| 4 |
Millennium Management
New York
|
+$241M |
| 5 |
Jennison Associates
New York
|
+$118M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
-$730M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$694M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$396M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$120M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$78.3M |
EW Hedge Fund Activity: Q2 2025 in Review
1,259 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q2 2025, worth a combined $39.4B — up 7.6% from $36.6B a quarter earlier.
Buyers outnumbered sellers: 164 funds opened new EW positions and 93 closed out — a net gain of 71 holders — while 423 added to existing stakes and 458 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $359M. The largest seller was Fisher Asset Management, cutting an estimated $730M.
- 1,259 institutional investors held Edwards Lifesciences (EW) as of Q2 2025, up from 1,204 in Q1 2025.
- Funds reported $39.4B of Edwards Lifesciences stock for Q2 2025, up 7.6% quarter-over-quarter.
- 164 funds opened new Edwards Lifesciences positions in Q2 2025 and 93 closed out, a net change of +71 holders.
- The largest Edwards Lifesciences buyer in Q2 2025 was JP Morgan Chase, an estimated $359M added.
- The largest Edwards Lifesciences seller in Q2 2025 was Fisher Asset Management, an estimated $730M sold.
Based on aggregated 13F filings for Q2 2025.